A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Hyun Ae JungKeon Uk ParkSang Hee ChoJinyeong LimKeun-Wook LeeMin Hee HongTak YunHo Jung AnWoong-Yang ParkSergio PereiraChan-Young OckBhumsuk KeamPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Nivolumab plus gemcitabine showed promising efficacy with favorable toxicity profiles in patients with advanced NPC in whom platinum-based combination chemotherapy failed.